188 related articles for article (PubMed ID: 38296162)
1. An update on new-age potential biomarkers for Parkinson's disease.
Soni R; Mathur K; Shah J
Ageing Res Rev; 2024 Feb; 94():102208. PubMed ID: 38296162
[TBL] [Abstract][Full Text] [Related]
2. Uncovering Novel Therapeutic Targets for Parkinson's Disease.
Soni R; Delvadia P; Joharapurkar A; Shah J
ACS Chem Neurosci; 2023 Jun; 14(11):1935-1949. PubMed ID: 37227448
[TBL] [Abstract][Full Text] [Related]
3. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
4. Retinal Changes in Parkinson's Disease: A Non-invasive Biomarker for Early Diagnosis.
Subramaniam MD; Aishwarya Janaki P; Abishek Kumar B; Gopalarethinam J; Nair AP; Mahalaxmi I; Vellingiri B
Cell Mol Neurobiol; 2023 Nov; 43(8):3983-3996. PubMed ID: 37831228
[TBL] [Abstract][Full Text] [Related]
5. The Potential Roles of Extracellular Vesicles as Biomarkers for Parkinson's Disease: A Systematic Review.
Valencia J; Ferreira M; Merino-Torres JF; Marcilla A; Soriano JM
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232833
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in Parkinson's disease (recent update).
Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
[TBL] [Abstract][Full Text] [Related]
7. Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson's disease.
Riederer P; Monoranu C; Strobel S; Iordache T; Sian-Hülsmann J
J Neural Transm (Vienna); 2021 Oct; 128(10):1577-1598. PubMed ID: 34636961
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways.
Park JS; Choe K; Lee HJ; Park TJ; Kim MO
J Biomed Sci; 2023 Aug; 30(1):66. PubMed ID: 37568205
[TBL] [Abstract][Full Text] [Related]
9. Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease.
Brockhausen I; Schutzbach J; Wang J; Fishwick B; Brockhausen J
Glycoconj J; 2022 Feb; 39(1):55-74. PubMed ID: 34757539
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Parkinson's disease: present and future.
Miller DB; O'Callaghan JP
Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818
[TBL] [Abstract][Full Text] [Related]
11. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit.
Tozzi A; Sciaccaluga M; Loffredo V; Megaro A; Ledonne A; Cardinale A; Federici M; Bellingacci L; Paciotti S; Ferrari E; La Rocca A; Martini A; Mercuri NB; Gardoni F; Picconi B; Ghiglieri V; De Leonibus E; Calabresi P
Brain; 2021 Dec; 144(11):3477-3491. PubMed ID: 34297092
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
13. Motor deficits and beta oscillations are dissociable in an alpha-synuclein model of Parkinson's disease.
Brys I; Nunes J; Fuentes R
Eur J Neurosci; 2017 Aug; 46(3):1906-1917. PubMed ID: 28370471
[TBL] [Abstract][Full Text] [Related]
14. Role of platelet in Parkinson's disease: Insights into pathophysiology & theranostic solutions.
Beura SK; Panigrahi AR; Yadav P; Singh SK
Ageing Res Rev; 2022 Sep; 80():101681. PubMed ID: 35798236
[TBL] [Abstract][Full Text] [Related]
15. Cell senescence induced by toxic interaction between α-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease.
Shen QQ; Jv XH; Ma XZ; Li C; Liu L; Jia WT; Qu L; Chen LL; Xie JX
Acta Pharmacol Sin; 2024 Feb; 45(2):268-281. PubMed ID: 37674042
[TBL] [Abstract][Full Text] [Related]
16. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders.
Wise RM; Wagener A; Fietzek UM; Klopstock T; Mosharov EV; Zucca FA; Sulzer D; Zecca L; Burbulla LF
Neurobiol Dis; 2022 Dec; 175():105920. PubMed ID: 36351559
[TBL] [Abstract][Full Text] [Related]
17. Pathological Correlates of Cognitive Decline in Parkinson's Disease: From Molecules to Neural Networks.
Novikov NI; Brazhnik ES; Kitchigina VF
Biochemistry (Mosc); 2023 Nov; 88(11):1890-1904. PubMed ID: 38105206
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of α-Synuclein in Parkinson's Disease: From a Neuron-Glia Crosstalk Perspective.
Yi S; Wang L; Wang H; Ho MS; Zhang S
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499080
[TBL] [Abstract][Full Text] [Related]
19. Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease.
O'Hara DM; Kalia SK; Kalia LV
Br J Pharmacol; 2018 Aug; 175(15):3080-3089. PubMed ID: 29722028
[TBL] [Abstract][Full Text] [Related]
20. Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
Boi L; Pisanu A; Palmas MF; Fusco G; Carboni E; Casu MA; Satta V; Scherma M; Janda E; Mocci I; Mulas G; Ena A; Spiga S; Fadda P; De Simone A; Carta AR
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
